进行还是不进行中期PET:质疑GEP-NET患者PRRT期间中期评估的影响
该回顾性研究分析了119例接受177Lu-PRRT的GEP-NET患者中,2周期后中期评估对治疗决策的影响;83例完成4周期,36例提前终止(27例疾病进展、3例部分缓解后手术、5例毒性、1例死亡)。完成4周期者中位PFS为38.0个月(95%CI 32.2-43.8)。对37家德国大学医院的调查显示,17家常规进行中期评估。
要点
- 完成4周期者中位PFS为38.0个月(95%CI 32.2-43.8)
- 37家受访医院中17家常规进行中期评估,62%提供PRRT,其中74%常规在2周期后评估
核心结论
- 2周期PRRT后的中期PET有助于识别GEP-NET患者的早期进展。
- 标准化中期评估实践可提高临床结局的可比性并优化患者管理。
研究设计与样本
- 回顾性分析119例接受177Lu-PRRT的GEP-NET患者,采用MRI/CT/生长抑素受体显像在2周期后进行再分期评估。
- 基于中期PET结果的治疗决策在多学科肿瘤委员会会议上做出。
- 对37家德国大学医院进行在线调查,了解其中期评估实践及管理变化。
主要发现
- 119例中83例完成4周期PRRT;36例在2周期后终止:27例疾病进展、3例部分缓解后手术、5例毒性、1例死亡。
- 完成4周期者中位PFS为38.0个月(95%CI 32.2-43.8)。
- 37家受访医院中17家常规使用中期评估;62%报告为GEP-NET患者提供PRRT,其中74%在2周期PRRT后常规进行中期评估,主要使用PET/CT成像技术。
关键数值与推荐
- 完成4周期PRRT患者的中位PFS为38.0个月(95%CI 32.2-43.8)。
- 37家德国大学医院中62%提供PRRT,其中74%常规在2周期后行中期评估。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study aimed to analyze the impact of interim evaluation on the continuation of 177 Lu-based peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and to survey its usage across German university hospitals. PATIENTS AND METHODS: In 119 GEP-NET patients who underwent PRRT, we retrospectively assessed the results and therapeutic impact of restaging performed after 2 cycles using MRI/CT/somatostatin receptor imaging. Therapeutic decisions based on interim PET results were made in multidisciplinary tumor board meetings. Additionally, an online survey was conducted among 37 German university hospitals regarding their interim evaluation practices, focusing on the change in management. RESULTS: Of 119 patients, 83 completed 4 PRRT cycles; 36 stopped after 2: 27 showed PD, 3 had PR leading to surgery, 5 experienced toxicity, and 1 died. Those completing 4 cycles showed a median PFS of 38.0 months (95% confidence interval, 32.2-43.8). Seventeen of 37 surveyed hospitals routinely used interim evaluation. In a survey among 37 German university hospitals, 62% reported offering PRRT for GEP-NET patients, with 74% of these performing a routinely interim evaluation after 2 cycles of PRRT, primarily using PET/CT imaging techniques. CONCLUSIONS: Interim PET after 2 PRRT cycles helps to identify early progression in GEP-NET patients. Standardizing interim evaluation practices could enhance the comparability of clinical outcomes and optimize patient management.
引用
- Wetz C, Ruhwedel T, Rogasch JMM, et al. To Perform, or Not to Perform Interim PET: Questioning the Impact of Midtherapy Evaluation During PRRT in GEP-NET Patients. Clin Nucl Med. 2024. PMID: 39388313. doi:10.1097/RLU.0000000000005479
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。